GLOBAL VARICELLA INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE (2023 - 2030)

The Global Varicella Infectious Diseases Diagnostics Market was evaluated to be worth USD 296.49 Billion in 2023 and is projected to reach a value of USD 505.63 Billion by 2030, growing at a fast CAGR of 6.9% during the forecast period 2023-2030.

The market for diagnostic tests used to find the Varicella-Zoster Virus (VZV), which causes chickenpox and shingles, is referred to as the varicella infectious diseases diagnostics market. There are numerous diagnostic techniques available on the market, including serological tests, PCR, DFA, and enzyme-linked immunosorbent assays (ELISA). Due to the rising incidence of chickenpox and shingles, two viral infections that afflict millions of people globally, the market for diagnostics for Varicella infectious disorders is anticipated to expand. This market is expanding as a result of the increasing demand for precise and effective diagnostic tests for infectious diseases. There is fierce competition in the market, and numerous businesses provide a variety of varicella diagnostic tests. Numerous reasons, such as the increased prevalence of varicella, the creation of novel and cutting-edge diagnostic methods, and the rising demand for point-of-care testing, are driving the market. The rising demand for home-based diagnostic tests, which enable patients to monitor their conditions from the convenience of their homes, is also anticipated to be favorable for the market.

The varicella-zoster virus is the common infectious disease that causes varicella, often known as chickenpox. (VZV). The illness is very contagious and is easily transmitted through the air or by coming into touch with the rash of an afflicted person. Fever, tiredness, and a red, itchy rash are all signs of chickenpox.

Global Varicella Infectious Diseases Diagnostics Market Drivers:

Increased incidence of varicella and the development of advanced diagnostic techniques is fuelling market demand:

• The prevalence of varicella has been rising across the world, which has increased demand for diagnostic tests. The World Health Organization (WHO) estimates that 140 million cases of varicella occur annually throughout the world, resulting in hospitalizations and fatalities, especially in infants and individuals with compromised immune systems. More precise and dependable tests for varicella have been created as a result of developments in diagnostic technology. In order to detect the presence of the varicella virus in blood or other physiological fluids, molecular diagnostic procedures like the polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) have been developed.

Government initiatives and support is boosting global varicella infectious diseases diagnostics market demand:

• Varicella may now be quickly diagnosed in clinical settings thanks to point-of-care testing (POCT), which has increased demand for the tests. POCT equipment is small, portable, and user-friendly, allowing medical professionals to diagnose and treat patients effectively. Governments all across the world are launching immunization programs and promoting early diagnosis and treatment in an effort to stop the spread of varicella. As a result, the market for diagnostics for varicella infectious disorders has grown favorably as medical professionals increasingly rely on them to treat the illness.

• Global Varicella Infectious Diseases Diagnostics Market Challenges:

In many parts of the world, there is a lack of knowledge about varicella, and patients may wait until the illness has advanced to a severe level before seeking medical assistance. Access to medical facilities may also be restricted, which might make it difficult to diagnose and treat varicella.  The cost of some varicella diagnostic tests may prevent them from being used in areas with limited resources. Delays in diagnosis and therapy could result from this, which could have detrimental effects on how patients respond to treatment. Regulatory approval is required before diagnostic tests for varicella may be developed and commercialized, which can be a time-consuming and expensive procedure. This may limit the market's access to cutting-edge diagnostic technologies.

Global Varicella Infectious Diseases Diagnostics Market Opportunities:

The prevalence of varicella is significant in emerging areas like Latin America and Asia-Pacific, where there are big populations. Companies now have the chance to increase their market share in these areas and provide cutting-edge diagnostic tools to fulfil the escalating demand.

It is possible to enhance the adoption of diagnostic testing for varicella and improve access to healthcare in environments with limited resources by developing more affordable diagnostic assays. By facilitating early identification and treatment, the incorporation of varicella diagnostic tests into healthcare systems can contribute to better patient outcomes. Companies now have the chance to collaborate with healthcare professionals and offer packaged solutions that incorporate both diagnostic testing and treatment alternatives.

COVID-19 Impact on Global Varicella Infectious Diseases Diagnostics Market:

The COVID-19 pandemic has caused supply chain interruptions on a global scale, which has impacted the accessibility of varicella diagnostic tests. Due to the COVID-19 pandemic's use of healthcare resources to treat COVID-19 cases, varicella diagnosis and treatment have been delayed. The demand for non-essential medical services, such as varicella diagnostic testing, has decreased as a result of the pandemic. The market has suffered as a result, especially for businesses that depend on the revenue from these services. The shift to digital diagnostics, including telemedicine and remote monitoring, has been expedited by the COVID-19 pandemic. Although this tendency has mostly affected other disease categories, it may eventually have an effect on the market for diagnostics for infectious disorders like varicella.

Global Varicella Infectious Diseases Diagnostics Market Recent Developments:

• In February 2022, a novel automated nucleic acid test for the varicella-zoster virus was introduced by Roche. The test offers high sensitivity and specificity and is made to be used on the cobas 6800/8800 equipment owned by the business.

• In September 2022, the introduction of a new varicella-zoster virus IgG assay was announced by Becton, Dickinson, and Company. The assay can produce results in as little as 15 minutes and is intended for use with the BD Veritor Plus System from the business.

• In August 2021, the introduction of a new varicella-zoster virus IgG antibody test was announced by Quest Diagnostics. The test can be used to confirm a diagnosis of varicella and is intended to assist medical professionals in evaluating a patient's immunological response to the virus.

• GLOBAL VARICELLA INFECTIOUS DISEASES DIAGNOSTICS  MARKET REPORT COVERAGE:

Global Varicella Infectious Diseases Diagnostics Market Segmentation:

Global Varicella Infectious Diseases Diagnostics Market Segmentation: By Type of Diagnostic Test

• PCR Tests

• ELISA Tests

• Rapid Diagnostic Tests (RDTs)

• Others

Molecular diagnostic procedures called Polymerase Chain Reaction (PCR) assays can identify the genetic makeup of the varicella-zoster virus in patient samples. These assessments are widely utilized in diagnostic laboratories and are quite sensitive and specific. Patient samples are used in Enzyme-Linked Immunosorbent Assay (ELISA) assays to identify antibodies against the varicella-zoster virus. These tests are perfect for use in clinical settings because they are simple to carry out, affordable, and yield quick findings. RDTs are straightforward, user-friendly diagnostic procedures that can find antibodies or antigens of the varicella-zoster virus in patient samples. These tests are perfect for use in point-of-care settings since they produce results quickly. Viral culture testing, immunofluorescence assays (IFAs), and serological tests are some of the diagnostic procedures for varicella infectious disorders.

Global Varicella Infectious Diseases Diagnostics Market Segmentation: By Application

• Diagnosis of Varicella

• Monitoring of Varicella Infections

• Research Applications

Antigen testing like ELISA and nucleic acid tests like PCR are examples of assays. The segment discusses the diagnostic procedures used to track the intensity and course of varicella infections in patients. Viral load studies, immunological assays, and imaging tests like CT or MRI are some examples of tests. The research application segment discusses the diagnostic procedures used in research settings to investigate the pathophysiology, epidemiology, and management of varicella infections. Sequencing, serological tests, and animal models are all examples of tests.

Global Varicella Infectious Diseases Diagnostics Market Segmentation: By End-User

• Hospitals

• Diagnostic Laboratories

• Research Centers

• Point-of-Care Settings

As they treat the greatest number of patients with varicella infections, hospitals are the primary end-users of diagnostics for varicella infectious illnesses. To identify and keep track of varicella infections in patients, hospitals use a variety of diagnostic techniques. Since they offer testing services to healthcare practitioners, diagnostic laboratories are also important to end users of diagnostics for infectious disorders like varicella. To find and keep track of varicella infections in patients, diagnostic laboratories use a variety of diagnostic assays. As they perform research to create novel diagnostic tests and therapies for varicella infections, research centers are another end-user of diagnostics for varicella infectious disorders. Diagnostic assays are also used by research institutions to track the population-wide transmission of varicella infections. Diagnostics for varicella infectious diseases are also widely used in point-of-care settings such as clinics, urgent care facilities, and emergency rooms.

Global Varicella Infectious Diseases Diagnostics Market Segmentation: By Region

• North America

• Europe

• Asia Pacific

• Rest of the World

Due to the high prevalence of varicella and the rising need for diagnostic tests, the North American market is anticipated to account for a sizeable portion of the global market. The development of the industry in this area is also being aided by the availability of a solid healthcare infrastructure and a focus on early diagnosis and treatment. Because varicella is becoming more common on the continent and there are more government attempts to stop its spread, the European market is likewise anticipated to experience significant development. The industry is expanding in Europe due to the presence of major market participants as well as improvements in diagnostic technology.

Global Varicella Infectious Diseases Diagnostics Market Key Players:

1. Abbott Laboratories

2. F. Hoffmann-La Roche Ltd.

3. Bio-Rad Laboratories, Inc.

4. DiaSorin S.p.A.

5. Thermo Fisher Scientific Inc.

6. Merck & Co., Inc.

7. Quidel Corporation

8. Siemens Healthineers AG

9. Becton, Dickinson and Company

10. BioMérieux SA